Aveo Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$120.0M
Doctors Paid
6,117
Transactions
18,498
2024 Total
$112.5M
Payment Breakdown by Category
Research$118.5M (98.7%)
Food & Beverage$343,629 (0.3%)
Consulting$206,843 (0.2%)
Travel$86,053 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $118.5M | 3,656 | 98.7% |
| Food and Beverage | $343,629 | 12,739 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $323,679 | 138 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $236,603 | 93 | 0.2% |
| Consulting Fee | $206,843 | 111 | 0.2% |
| Honoraria | $147,789 | 97 | 0.1% |
| Education | $91,542 | 1,284 | 0.1% |
| Travel and Lodging | $86,053 | 320 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $75,800 | 25 | 0.1% |
| Entertainment | $4,820 | 35 | 0.0% |
Payments by Type
Research
$118.5M
3,656 transactions
General
$1.5M
14,842 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | $115.1M | 8 | 3,396 |
| A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | $1.5M | 7 | 77 |
| TBD - WCT/AVEO | $1.5M | 4 | 158 |
| Phase II Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (FORTUNE) | $135,447 | 0 | 1 |
| Atezolizumab plus Tivozanib in Immunologically Cold Tumor Types (IMMCO-1) | $98,023 | 0 | 4 |
| A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma | $82,484 | 0 | 20 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Helen Moon, M.d, M.D | Internal Medicine | Pasadena, CA | $1,672 | $0 |
| Dr. Chad Cherington, M.d, M.D | Hematology & Oncology | Mesa, AZ | $1,646 | $0 |
| Yung Lyou, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Fullerton, CA | $1,644 | $0 |
| Dr. Yasser Ged, Mbss, Md, MBSS, MD | Medical Oncology | Baltimore, MD | $1,627 | $0 |
| Victor Lin, Md, Phd, MD, PHD | Hematology & Oncology | Baton Rouge, LA | $1,597 | $0 |
| Natalie Reizine, M.d, M.D | Internal Medicine | Chicago, IL | $1,565 | $0 |
| Dr. Thai Ho, M.d./Ph.d, M.D./PH.D | Internal Medicine | Scottsdale, AZ | $1,558 | $0 |
| Umasankar Ramadoss, Md, MD | Hematology & Oncology | Columbia, MO | $1,540 | $0 |
| Rao Mushtaq, Md, MD | Medical Oncology | Thornton, CO | $1,531 | $0 |
| Bruno Bastos, M.d, M.D | Hematology & Oncology | Miami Beach, FL | $1,527 | $0 |
| John Henegan, M.d, M.D | Hematology & Oncology | Jackson, MS | $1,521 | $0 |
| Dr. Benjamin Gartrell, Md, MD | Internal Medicine | Bronx, NY | $1,500 | $0 |
| Jianjun Gao, M.d, M.D | Medical Oncology | Houston, TX | $1,500 | $0 |
| Adedayo Onitilo, Md, MD | Hematology & Oncology | Weston, WI | $1,500 | $0 |
| Dr. Christian Thomas, Md, MD | Hematology & Oncology | Westbrook, ME | $1,500 | $0 |
| Dr. Peng Wang, M.d., Ph.d, M.D., PH.D | Medical Oncology | Lexington, KY | $1,500 | $0 |
| Kevin Kim, M.d, M.D | Medical Oncology | San Francisco, CA | $1,500 | $0 |
| Rohit Jain, M.b.b.s, Mph, M.B.B.S, MPH | Hematology & Oncology | Tampa, FL | $1,500 | $0 |
| Dr. David Chism, Md, MD | Internal Medicine | Knoxville, TN | $1,500 | $0 |
| Dr. David Waterhouse, Md, MD | Hematology & Oncology | Cincinnati, OH | $1,480 | $0 |
| Dr. Andrew Hahn, M.d, M.D | Internal Medicine | Houston, TX | $1,480 | $0 |
| Dr. Veena Charu, M.d, M.D | Specialist | Anaheim, CA | $1,451 | $0 |
| Dr. Bety Ciobanu, Md, MD | Hematology & Oncology | Chicago, IL | $1,411 | $0 |
| Nicholas Vogelzang, Md, MD | Hematology & Oncology | Las Vegas, NV | $1,407 | $0 |
| David Mcdermott, Md, MD | Hematology & Oncology | Boston, MA | $1,400 | $0 |
About Aveo Pharmaceuticals, Inc.
Aveo Pharmaceuticals, Inc. has made $120.0M in payments to 6,117 healthcare providers, recorded across 18,498 transactions in the CMS Open Payments database. In 2024, the company paid $112.5M. The top product by payment volume is FOTIVDA ($118.4M).
Payments were distributed across 110 medical specialties. The top specialty by payment amount is Hematology & Oncology ($637,565 to 1,581 doctors).
Payment categories include: Food & Beverage ($343,629), Consulting ($206,843), Research ($118.5M), Travel & Lodging ($86,053).
Aveo Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.